文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

兰地洛尔与脓毒性休克患者器官衰竭:STRESS-L随机临床试验

Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

STRESS-L是一项开放标签、多中心随机试验,纳入126例接受去甲肾上腺素持续治疗至少24小时且心率≥95次/分的脓毒性休克成人患者,比较标准治疗联合兰地洛尔输注与单纯标准治疗。主要结局为随机化至14天的平均SOFA评分,兰地洛尔组为8.8(3.9),标准治疗组为8.1(3.2),平均差0.75(95%CI -0.49至2.0;P=0.24),差异无统计学意义。试验因可能有害的早期信号提前终止,结果不支持在此类患者中使用兰地洛尔控制心动过速。

要点

  • 在需要去甲肾上腺素持续治疗超过24小时的脓毒性休克伴心动过速患者中,兰地洛尔输注未降低14天内SOFA评分。
  • 兰地洛尔组28天死亡率37.1%,标准治疗组25.4%,绝对差11.7%(95%CI -4.4%至27.8%;P=0.16)。
  • 试验因独立数据监测委员会建议提前终止,因不太可能显示获益且可能存在伤害。

核心结论

  • 在脓毒性休克伴心动过速且接受去甲肾上腺素治疗超过24小时的患者中,兰地洛尔输注未降低随机化后14天内以SOFA评分衡量的器官衰竭。
  • 这些结果不支持在因确诊脓毒性休克接受去甲肾上腺素治疗的患者中使用兰地洛尔控制心动过速。

研究设计与样本

  • 开放标签、多中心、随机临床试验,在英国40个国民健康服务体系重症监护病房开展,2018年4月至2021年12月进行,因可能有害的信号于2021年12月提前终止。
  • 纳入126例成人(≥18岁)脓毒性休克伴心动过速(心率≥95次/分)且接受去甲肾上腺素持续治疗至少24小时的患者,随机分为标准治疗组63例和兰地洛尔输注组63例。
  • 计划样本量为340例,实际入组126例(37%);平均年龄55.6岁(95%CI 52.7至58.5岁),男性占58.7%。

主要发现

  • 兰地洛尔组平均SOFA评分为8.8(标准差3.9),标准治疗组为8.1(标准差3.2),平均差0.75(95%CI -0.49至2.0;P=0.24)。
  • 随机化后28天死亡率:兰地洛尔组37.1%(62例中23例),标准治疗组25.4%(63例中16例),绝对差11.7%(95%CI -4.4%至27.8%;P=0.16)。
  • 随机化后90天死亡率:兰地洛尔组43.5%(62例中27例),标准治疗组28.6%(63例中18例),绝对差15%(95%CI -1.7%至31.6%;P=0.08)。
  • 两组发生至少一次不良事件的患者数量无差异。

临床怎么用

  • 原文结论指出,这些结果不支持在因确诊脓毒性休克接受去甲肾上腺素治疗的患者中使用兰地洛尔控制心动过速。

局限性

  • 试验因独立数据监测委员会建议提前终止,因不太可能显示获益且可能存在伤害。
  • 计划样本量为340例,实际仅入组126例(37%)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Patients with septic shock undergo adrenergic stress, which affects cardiac, immune, inflammatory, and metabolic pathways. β-Blockade may attenuate the adverse effects of catecholamine exposure and has been associated with reduced mortality. OBJECTIVES: To assess the efficacy and safety of landiolol in patients with tachycardia and established septic shock requiring prolonged (>24 hours) vasopressor support. DESIGN, SETTING, AND PARTICIPANTS: An open-label, multicenter, randomized trial involving 126 adults (≥18 years) with tachycardia (heart rate ≥95/min) and established septic shock treated for at least 24 hours with continuous norepinephrine (≥0.1 μg/kg/min) in 40 UK National Health Service intensive care units. The trial ran from April 2018 to December 2021, with early termination in December 2021 due to a signal of possible harm. INTERVENTION: Sixty-three patients were randomized to receive standard care and 63 to receive landiolol infusion. MAIN OUTCOMES AND MEASURES: The primary outcome was the mean Sequential Organ Failure Assessment (SOFA) score from randomization through 14 days. Secondary outcomes included mortality at days 28 and 90 and the number of adverse events in each group. RESULTS: The trial was stopped prematurely on the advice of the independent data monitoring committee because it was unlikely to demonstrate benefit and because of possible harm. Of a planned 340 participants, 126 (37%) were enrolled (mean age, 55.6 years [95% CI, 52.7 to 58.5 years]; 58.7% male). The mean (SD) SOFA score in the landiolol group was 8.8 (3.9) compared with 8.1 (3.2) in the standard care group (mean difference [MD], 0.75 [95% CI, -0.49 to 2.0]; P = .24). Mortality at day 28 after randomization in the landiolol group was 37.1% (23 of 62) and 25.4% (16 of 63) in the standard care group (absolute difference, 11.7% [95% CI, -4.4% to 27.8%]; P = .16). Mortality at day 90 after randomization was 43.5% (27 of 62) in the landiolol group and 28.6% (18 of 63) in the standard care group (absolute difference, 15% [95% CI, -1.7% to 31.6%]; P = .08). There were no differences in the number of patients having at least one adverse event. CONCLUSION AND RELEVANCE: Among patients with septic shock with tachycardia and treated with norepinephrine for more than 24 hours, an infusion of landiolol did not reduce organ failure measured by the SOFA score over 14 days from randomization. These results do not support the use of landiolol for managing tachycardia among patients treated with norepinephrine for established septic shock. TRIAL REGISTRATION: EU Clinical Trials Register Eudra CT: 2017-001785-14; isrctn.org Identifier: ISRCTN12600919.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Whitehouse T, Hossain A, Perkins GD, et al. Landiolol and Organ Failure in Patients With Septic Shock: The STRESS-L Randomized Clinical Trial. JAMA. 2023. PMID: 37877587. doi:10.1001/jama.2023.20134

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。